Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs

Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs

FinvizFinviz2026/02/12 09:27
By:Finviz

Novo Nordisk (NYSE:NVO) CEO Mike Doustdar said the company aims to reach about 15 million new patients when Medicare begins covering obesity treatments later this year.

While roughly 67 million Americans are on Medicare, he noted that around 15 million fall within the “target group” for the Danish drugmaker’s products. Doustdar, in an interview with CNBC on Wednesday, said Medicare coverage and the rollout of Novo's new obesity pill, among other factors, are expected to increase prescription volumes gradually and help offset lower U.S. prices following the company's agreement with President Donald Trump.

However, the CEO said that the Medicare coverage for obesity treatments is unlikely to expand quickly, noting that expecting rapid access would be unrealistic. Doustdar pointed to the slow uptake among commercially insured eligible patients as a sign that adoption will likely take time.

He also said that the company is currently negotiating with the government to finalize the exact timing for the opening, including the specific month and week.

GLP-1 Price Cuts, Medicare Expansion

In November, Trump announced agreements with Eli Lilly (NYSE:LLY) and Novo Nordisk to significantly lower prices of their GLP-1 obesity and diabetes drugs.

On the newly launched TrumpRx website, Wegovy pills are listed at $149, roughly an 89% discount to prevailing market prices, while Wegovy and Ozempic pens start at $199 each. Meanwhile, Eli Lilly's Zepbound is priced from $299 per vial, reflecting an estimated 72% discount.

The deals will also expand Medicare and Medicaid coverage for the treatments starting in mid-2026. Previous reports suggested that Medicare will begin covering approved injectable and oral GLP-1 obesity treatments for the first time, with patients required to pay a $50 copay.

Novo Faces GLP-1 Pressure, As Lilly Surges

Novo is facing mounting pressure to regain market share in the fast-growing GLP-1 market amid competition from Eli Lilly and lower-cost compounded alternatives. On Monday, Novo sued Hims & Hers (NYSE:HIMS), for mass marketing cheaper, unapproved copies of its new Wegovy obesity pill and injections in the U.S.

The company also issued weak guidance for its 2026 sales and operating profit. The sales outlook is being pressured by lower realized prices, including effects from the U.S. "Most Favoured Nations" agreement, patent expirations for semaglutide in some international markets, and rising competition.

On the other hand, Eli Lilly expects revenue of $80–$83 billion, surpassing Wall Street's $77.62 billion forecast, with the midpoint implying 25% growth.

When asked how Novo plans to narrow the gap, Doustdar said one approach is "to do better on the pill."

Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs image 0

Benzinga's Edge Rankings place Novo Nordisk in the 77th percentile for quality and the 31st percentile for value, reflecting its mixed performance. Benzinga’s screener allows you to compare NVO’s performance with its peers.

Price Action: Over the past year, Novo Nordisk stock declined 40.41%, as per data from Benzinga Pro. On Wednesday, the stock fell 0.77% to close at $48.74.

Image via Shutterstock

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "AI slowdown theory" can't stop the funding frenzy of model giants! Astra is launched, sparking heated discussions on AGI; OpenAI aims for a $1.2 trillion valuation

OpenAI is in early talks with investors to discuss a new round of financing, which would bring the valuation of ChatGPT's creator OpenAI to over $1.2 trillion. The company will subsequently conduct its initial public offering (IPO).

智通财经2026/09/16 01:11
The "AI slowdown theory" can't stop the funding frenzy of model giants! Astra is launched, sparking heated discussions on AGI; OpenAI aims for a $1.2 trillion valuation

White House Pressure Fails to Prevent Hawkish Shift! Federal Reserve Rate Hike Looms, Waller-Trump Relationship Faces Major Test

The Federal Reserve is expected to raise interest rates by 25 basis points on Wednesday, marking the first increase since 2023; the market is pricing in a probability of over 90%, and the relationship between the White House and Walsh faces a test.

智通财经2026/09/16 01:06
White House Pressure Fails to Prevent Hawkish Shift! Federal Reserve Rate Hike Looms, Waller-Trump Relationship Faces Major Test